Oxford Genetics has launched a collaboration with the Cell and Gene Therapy Catapult (CGT Catapult), a UK Government-funded industry accelerator. 13 May 2019
FUJIFILM Diosynth Biotechnologies is expanding its footprint in the UK with a new investment in a BioCampus project, worth up to £12.6 million with a subsidy from the Tess Valley Combined Authority (TVCA). 30 April 2019
Cambridge, UK-based Bicycle Therapeutics has filed a prospectus with the US Securities and Exchange Commission (SEC) for an initial public offering (IPO) priced at around $86 million. 30 April 2019
Acacia Pharma has added to the positive data on Barhemsys (intravenous amisulpride) as a rescue treatment in established post-operative nausea & vomiting. 26 April 2019
Daiichi Sankyo has exercised its 2016 option with Zymeworks, for a license to a proprietary immuno-oncology bispecific built on Zymeworks’ Azymetric and EFECT platforms. 26 April 2019
Austrian company Marinomed Biotech has successfully completed the pivotal Phase III study of Budesolv (budesonide), a nasal spray for the treatment of allergic rhinitis. 23 April 2019
Therillia Development Co, a Montreal-based subsidiary of Sanderling Ventures Canada investor in early-stage biotech companies, has acquired Tavec Pharmaceuticals, the leading therapeutic exosome company and is moving its head office from New York to Montreal. 20 April 2019
Belgian biopharma UCB has happily announced that the National Institute for Health and Care Excellence (NICE) has issued its final guidance recommending use of its treatment for severe plaque psoriasis within the National Health Service in England. 18 April 2019
The UK subsidiary of Akcea Therapeutics today announced that the National Institute for Health and Care Excellence (NICE) has issued a positive Final Evaluation Document (FED) for Tegsedi (inotersen) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). 16 April 2019
US ophthalmology specialist Ophthotech Corporation has given itself a new name to reflect its change to becoming a company focused on discovering and developing gene therapies to treat orphan inherited retinal diseases for which there are no other treatments. 16 April 2019
US biotech Gilead Sciences and Danish diabetes giant Novo Nordisk are to collaborate on a trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (NASH). 15 April 2019
In a third deal within the space of one month, Chinese biotech firm HitGen has entered into a license agreement to develop a novel class of drugs with Japan’s Kaken Pharmaceutical. 11 April 2019
Dutch biotech Synaffix, which is exclusively focused on continued advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the development of best-in-class ADCs, has entered into a license agreement with Shanghai Miracogen, a Chinese biotechnology company with a clinical-stage pipeline of ADCs. 10 April 2019
Shares in US biotech United Therapeutics slipped by 6% on Monday after the company announced that it was ending development of esuberaprost following a failed trial in pulmonary arterial hypertension (PAH). 9 April 2019
China’s clinical-stage biopharma firm Antengene, today announced the establishment of its US subsidiary and plans for collaborations with the non-profit Baruch S Blumberg Institute. 8 April 2019
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024